Dr Suresh Jadhav | Executive Director
Serum Institute of India

Dr Suresh Jadhav, Executive Director, Serum Institute of India

Dr.Suresh Jadhav, M.Pharm., Ph.D. is the Executive Director of Serum Institute of India Pvt. Ltd., one of the largest vaccine manufacturers from the developing countries, supplying vaccines to more than 170 countries through U.N. Agencies at most affordable prices.  His 45 years technical expertise includes QC/QA/cGMP/GLP/GCP techniques, inspections of laboratories and validation of various production and quality control processes, pharma/toxicological screening of various drugs, toxins & venoms etc. & drugs pricing.  Dr.Jadhav also led the project of development and introduction of Meningococcal A Conjugate Vaccine in Sub-Saharan African belt, the development of Seasonal & Pandemic Influenza Vaccines and also played major role in acquisition of Bilthoven Biologicals, a Netherlands based Govt. Vaccine manufacturing company.  Dr.Jadhav is also associated with DCVMN since its inception in 2000 and was the President of DCVMN from 2003 till 2008.  He held the positions of GAVI Board / Alternate member as also member of GAVI PPC.  He is currently member on various boards i.e. European Vaccine Initiative, FastVac, and Health Innovation in Practice Board.  He is closely associated with various advisory committees e.g. Task Force of Sabin Vaccine Institute, WHO IVR-IVAC and Decades of Vaccines (DoV) etc. Dr.Jadhav is also affiliated with several Indian universities, AICTE, UGC, State Directorate of Technical Education etc. He is also a recognized guide for M.Pharm and Ph.D students and has so far guided more than 30 students. He is the Chairman of Expert Committee on Vaccines and other Biologicals and also a member on the Scientific Body of Indian Pharmacopoeia Commission.   He has participated in several collaborative studies for making revisions in international reference standards for WHO, NIBSC, NVI/RIVM etc. and has published more than 100 technical papers in national & international journals, with extensive travel throughout the globe.   He has to his credit two patents in his name. Ranked at 7th position amongst Worlds 50 most influential people in Vaccines surveyed by Vaccinenation of Terrapinn. He is conferred with IPA Pune Lifetime Achievement Award 2015 by Indian Pharmaceutical Association.


Day Two 11th October, Human @ 09:10

Plenary discussion: Where is the global vaccine industry shifting to for new collaborations? Perspectives from emerging markets and Asia

  • The role of emerging markets in the global supply and demand for vaccines
  • What vaccine technologies and vaccine candidates are favourable?
  • Does it align with other philanthropy organisations?
  • The role of Public-Public Partnerships (P2Ps) in vaccine R&D for poverty related and neglected diseases (PRNDs)
  • Priorities for linking new vaccine development with public health in low and middle income countries

back to speakers